Cannabis-based medicinal products (Sativex)
- Status:
- Do Not Prescribe (DNP), Red, Green - after consultant/specialist initiation
- Decision Date:
- December 2019
Comments
Cannabis - based products listed in NICE NG144 include:
-
Nabilone
-
THC:CBD (combination of delta-9-tetrahydrocannabinol with cannabidiol - Sativex)
-
Dronabinol
-
THC (delta-9-tetrahydrocannabinol)
-
Cannabidiol (Epidyolex) with clobazam
JAPC classification for each NICE indication:
GREEN after consultant/specialist initiation:
RED:
- NICE NG144: Seizures associated with Lennox-Gastaut syndrome & Dravet syndrome. (See also TA614 & TA615 below). (NHSE commissioned).
-
NICE TA614 - Cannabidiol (Epidyolex) with clobazam for treating seizures associated with Dravet syndrome. (NHSE commissioned). (Decision date - January 2020).
-
NICE TA615 - Cannabidiol (Epidyolox) with clobazam for treating seizures associated with Lennox-Gastaut syndrome. (NHSE commissioned) (Decision date - January 2020).
- NICE TA873 - Cannabidiol for treating
seizures caused by tuberous sclerosis complex. (NHSE commissioned) (Decision date - April 2023)
Do Not Prescribe (DNP):
- NICE NG144 - intractable nausea and vomiting. (NHSE commissioned).
-
-
NICE NG144 - severe treatment - resistant epilepsy. (NHSE commissioned).
Red Drug Classifications
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again